Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
Best estimates of the risk of VTE with a number of ethinylestradiol/progestogen combinations compared with the risk associated with levonorgestrel-containing pills are shown in table below. Compared with pregnancy and the postpartum period, the risk of VTE associated with using CHCs is lower.
Risk of VTE with combined hormonal contraceptives
Progestogen in CHC (combined with ethinylestradiol, unless stated) | Relative risk vs levonorgestrel | Estimated incidence (per 10,000 women per year of use) |
Non-pregnant non-user | - | 2 |
Levonorgestrel | Ref | 5-7 |
Norgestimate / Norethisterone | 1.0 | 5-7 |
Gestodene / Desogestrel / Drospirenone | 1.5-2.0 | 9-12 |
Etonogestrel / Norelgestromin | 1.0-2.0 | 6-12 |
Chlormadinone2 / Dienogest/ Nomegestrel acetate (E2) | TBC | TBC |
E2 -estradiol; TBC -to be confirmed
1 Further studies are ongoing or planned to collect sufficient data to estimate the risk for these products
2 Not currently available in the UK
There is no evidence for differences between low dose CHCs (ethinylestradiol <50µg) in their risk of arterial thromboembolism (ATE).
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.